More Company News

Oxford BioDynamics

Restoration of trading on AIM
06 Oct 2026Read More

Oxford BioDynamics

Results of placing and subscription
06 Oct 2026Read More

Oxford BioDynamics

Publication of Circular, Notice of General Meeting and Proposed Share Consolidation
02 Oct 2026Read More

Oxford BioDynamics

Capital access window
30 Sep 2026Read More

Oxford BioDynamics

Interim H126 results
30 Sep 2026Read More

Oxford BioDynamics

Submission of US NDA for Orpathys+Tagrisso in MET-Driven EGFR-Mutated NSCLC
29 Sep 2026Read More

Oxford BioDynamics

Phase I initiation of KRAS-EGFR-Antibody Conjugate HMPL-A830
28 Sep 2026Read More

Oxford BioDynamics

Further demonstration of AVA6103 potential at AACR Conference on Pancreatic Cancer
25 Sep 2026Read More

Oxford BioDynamics

Clinical data to be presented at ESMO 2026
24 Sep 2026Read More

Oxford BioDynamics

Completion of up to US$25m in debt financing
24 Sep 2026Read More

1 2 3 4 … 100
Return to Oxford BioDynamics
© 2019-2026 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).